Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

166
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
166
Cancer Therapies02:49

Cancer Therapies

8.0K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.0K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Drug Dosage Regimen: Overview01:15

Drug Dosage Regimen: Overview

3.8K
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
3.8K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

2.1K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reporting of primary endpoint and associated spin in randomized myeloma trials.

The oncologist·2026
Same author

A Single-Arm Phase 2 Trial of Doxorubicin Plus Zalifrelimab (Anti-CTLA-4 Antibody) and Balstilimab (Anti-PD-1 Antibody) in Advanced/Metastatic Soft Tissue Sarcomas.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

Novel <i>PLEC-EML4-ALK</i> Double Fusion Underlying Crizotinib Resistance in a Metastatic Inflammatory Myofibroblastic Tumor: A Case Report.

JTO clinical and research reports·2025
Same author

Prevalence of Adverse Event Reporting in Adolescents and Young Adults Enrolled in Cancer Clinical Trials.

JCO oncology practice·2023
Same author

Current therapies and future prospective for locally aggressive mesenchymal tumors.

Frontiers in oncology·2023
Same author

Quality of content reporting on two major oncology media websites: OncLive and Targeted Oncology.

Journal of cancer policy·2023

Related Experiment Video

Updated: Sep 17, 2025

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

18.4K

Interrupted Systemic Therapy (Drug Holiday) for Metastatic Sarcoma: Is It Safe?

Alessandra Maleddu1, Cole Wayant2

  • 1Department of Medicine, University of Colorado Anschutz Medical Campus, 1665 Aurora Ct, MS F704, Room 5328, Aurora, CO, 80045, USA. alessandra.maleddu@cuanschutz.edu.

Current Treatment Options in Oncology
|June 27, 2025
PubMed
Summary
This summary is machine-generated.

Metastatic sarcoma treatment is challenging. This review explores drug holidays to improve quality of life while maintaining overall survival in sarcoma patients.

Keywords:
Chemotherapy holidayPalliative chemotherapyPatient reported outcomesQuality of lifeSarcoma

More Related Videos

Practical Considerations in Studying Metastatic Lung Colonization in Osteosarcoma Using the Pulmonary Metastasis Assay
07:44

Practical Considerations in Studying Metastatic Lung Colonization in Osteosarcoma Using the Pulmonary Metastasis Assay

Published on: March 12, 2018

10.3K
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

9.7K

Related Experiment Videos

Last Updated: Sep 17, 2025

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

18.4K
Practical Considerations in Studying Metastatic Lung Colonization in Osteosarcoma Using the Pulmonary Metastasis Assay
07:44

Practical Considerations in Studying Metastatic Lung Colonization in Osteosarcoma Using the Pulmonary Metastasis Assay

Published on: March 12, 2018

10.3K
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

9.7K

Area of Science:

  • Oncology
  • Medical Oncology
  • Sarcoma Research

Background:

  • Sarcomas are rare, aggressive mesenchymal tumors with limited treatment options for metastatic disease.
  • Current chemotherapy regimens for metastatic sarcoma are toxic and offer poor outcomes.
  • New strategies are needed to balance disease control and patient quality of life.

Purpose of the Study:

  • To review the literature on drug holidays in sarcoma management.
  • To provide guidance on the role and feasibility of planned treatment breaks.
  • To assess the impact of treatment holidays on overall survival and quality of life.

Main Methods:

  • Literature review of studies on drug holidays in metastatic sarcoma.
  • Analysis of data regarding treatment efficacy and toxicity.
  • Evaluation of impact on patient-reported outcomes and overall survival.

Main Results:

  • Drug holidays may improve quality of life for metastatic sarcoma patients.
  • The impact of treatment breaks on overall survival remains incompletely understood.
  • Optimal duration and feasibility of planned treatment holidays require further investigation.

Conclusions:

  • Drug holidays represent a potential strategy to enhance quality of life in metastatic sarcoma.
  • Further research is crucial to define the optimal use of treatment breaks without compromising survival.
  • Clinicians need updated guidance for managing metastatic sarcoma with a focus on palliative care and quality of life.